secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093342
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q2 net loss $33.7M; gets FDA Breakthrough Therapy Designation for atacicept in IgAN
--------------------------------------------------------------------------------

- Net loss $33.7M ($0.62/diluted share) vs $20.2M ($0.46) in Q2 2023; cash $384.4M sufficient through approval and US launch.
- FDA granted Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN).
- Phase 2b ORIGIN data: atacicept stabilized kidney function through 72 weeks, reduced hematuria; 96-week data expected Q4 2024.
- Phase 3 ORIGIN 3 enrollment on track to complete Q3 2024; topline data expected Q2 2025.
- Appointed David L. Johnson COO, Amit Sharma EVP Medical Affairs; Christy J. Oliger to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017024093342/0000950170-24-093342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017024093342/vera-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer